Skip to search formSkip to main contentSkip to account menu

cilostazol

Known as: 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one, Cilostazole, cilostazol [Chemical/Ingredient] 
A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of… 
National Institutes of Health

Related topics

Related topics

20 relations

Broader (7)

Bronchodilator AgentsFibrinolytic AgentsNeuroprotective AgentsPhosphodiesterase 3 Inhibitors
CYP3A7 protein, humanCongestive heart failureGraft Occlusion, VascularHypersensitivity

Narrower (2)

OPC 13013Pletal

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury
Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase… 
2008
2008
Cilostazol attenuates MCP‐1 and MMP‐9 expression in vivo in LPS‐administrated balloon‐injured rabbit aorta and in vitro in LPS‐treated monocytic THP‐1 cells
Monocyte chemoattractant protein‐1 (MCP‐1) and matrix metalloproteinase‐9 (MMP‐9) are involved in vascular inflammation. We… 
Highly Cited
2006
Highly Cited
2006
Cilostazol Suppresses Superoxide Production and Expression of Adhesion Molecules in Human Endothelial Cells via Mediation of cAMP-Dependent Protein Kinase-Mediated Maxi-K Channel Activation
This study shows whether increased intracellular cAMP level by cilostazol is directly coupled to its maxi-K channel activation in… 
2005
2005
Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery.
BACKGROUND Although percutaneous transluminal angioplasty (PTA) is being widely used for the treatment of stenosis of peripheral… 
2000
2000
6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2.
1999
1999
Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
1998
1998
Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation.
Cilostazol inhibits intimal hyperplasia after stent implantation into canine iliac arteries. To determine the antiproliferative… 
1996
1996
Nerve function and blood flow in Otsuka Long-Evans Tokushima Fatty rats with sucrose feeding: effect of an anticoagulant.
1985
1985
Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.
A new antithrombotic drug, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)- qui nolinone, OPC-13013… 
1985
1985
The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man.
The metabolism of cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)- qui nolinone, OPC-13013) was studied… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)